Severe reactive ischemic posterior segment inflammation in acanthamoeba keratitis: a new potentially blinding syndrome.
OBJECTIVE
To describe a newly recognized clinical syndrome in Acanthamoeba keratitis consisting of severe reactive ischemic posterior segment vascular inflammation.


METHODS
Noncomparative, retrospective, single-institution observational case series.


METHODS
Five eyes of 5 patients with Acanthamoeba keratitis.


METHODS
A retrospective review of the records of patients diagnosed with Acanthamoeba keratitis between January 1, 1995, and December 1, 2005, was conducted to identify those who underwent eventual enucleation. Five enucleated eyes of 118 eyes with Acanthamoeba keratitis were identified.


METHODS
History, clinical examination results, available laboratory study results, and histopathologic examination results.


RESULTS
Histopathologic examination showed Acanthamoeba cysts in the cornea in 4 eyes, whereas it failed to demonstrate amebic cysts or trophozoites in the posterior segment of all eyes studied and unexpectedly revealed chronic chorioretinal inflammation with perivascular lymphocytic infiltration and diffuse neuroretinal ischemia in 4 of 5 eyes. Retinal artery thrombosis was present in 3 of the 4 involved eyes, and central retinal artery and vein thrombosis was found in 1 eye. Hematologic studies in 3 patients showed abnormal anticardiolipin antibody levels in 1 patient and factor V Leiden deficiency in another.


CONCLUSIONS
Prolonged Acanthamoeba keratitis can result in a severe sterile ischemic posterior segment inflammation that is potentially blinding, especially in patients with underlying hypercoagulation disorders.
Awwad
Shady T
ST
Cornea and External Diseases, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9057, USA.
Heilman
Michelle
M
Hogan
R Nick
RN
Parmar
Dipak N
DN
Petroll
W Matthew
WM
McCulley
James P
JP
Cavanagh
H Dwight
HD
D015823:Acanthamoeba Keratitis / Q000150:complications*; D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D001766:Blindness / Q000209:etiology* / Q000601:surgery; D002825:Chorioretinitis / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000601:surgery; D015353:Eye Enucleation; D005165:Factor V / Q000378:metabolism; D005260:Female; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000276:immunology; D007511:Ischemia / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000601:surgery; D008214:Lymphocytes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015356:Retinal Artery Occlusion / Q000175:diagnosis / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000209:etiology; D012171:Retinal Vessels / Q000473:pathology*; D012189:Retrospective Studies; D013577:Syndrome
D017153:Antibodies, Anticardiolipin; C095381:factor V Leiden; D005165:Factor V